Champions Oncology, Inc.

NASDAQ:CSBR

Biotechnology

Healthcare
$4.44 -1.17%

-$0.08 today

Market cap
$61.80M
Beta
0.40
P/E (TTM)
-41.0
EPS (TTM)
-$0.16
52W Low $5.50High $9.63

Volume 0.01M

Average 0.01M

CSBR Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Champions Oncology, Inc.NASDAQ: CSBR

Revenue · Q3 FY2026 · quarter ended Jan 2026

Revenue declines year over year

Q3 FY2026 revenue of $16.56M fell 2.8% year over year, behind the -1.1% change in trailing-twelve-month revenue. Sequentially, it rose 10.1% from the prior quarter. Over 3 fiscal years it compounded at +5.1% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 1 analysts of $58.53M (+2.8%) for the fiscal year ending Apr 2026, a slowdown from the +13.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJan 2026
$16.56M+10.1% QoQ
Last fiscal yearApr 2025
$56.94M+13.5% YoY
LTMJan 2026
$57.94M-1.1% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.8%+4.3%+7.1 pp
1 year+13.5%+2.8%-10.8 pp
3-year CAGR+5.1%+7.5%+2.5 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
56.94M USD
Year-over-year change
+13.5%
4-year CAGR
+8.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How CSBR compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -1.1% is the 2nd highest of 7, against a peer median of -83.4%.
  • Over three fiscal years its annual growth of +5.1% compares with a peer median of +14.8%.
CSBR Competitors
Revenue for CSBR and competitors
Company Period LTM YoY 3-year CAGR
STROSutro Biopharma, Inc.LTM Mar 2026$99.61M USD+49.9%+14.8%
CSBRChampions Oncology, Inc.LTM Jan 2026$57.94M USD-1.1%+5.1%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$23.14M USD-88.4%+23.9%
STTKShattuck Labs, Inc.LTM Mar 2026$1M USD-78.3%+15.3%
CNTBConnect Biopharma Holdings LimitedFY2025$64K USD-99.8%—
IFRXInflaRx N.V.LTM Mar 2026€29.33K EUR-77.4%—
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$0 USD——
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$0 USD-100.0%-9.6%
IMAImageneBio IncLTM Mar 2026$0 USD—-62.9%
KLRSKalaris Therapeutics IncLTM Mar 2026$0 USD——
Peer median (excluding CSBR) —-83.4%+14.8%

Competitors are the stored peer set for CSBR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Apr 2021
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
Revenue41.04M49.11M53.87M50.16M56.94M
Cost of Revenue21.45M23.63M29.53M29.4M28.39M
Gross Profit19.59M25.48M24.34M20.75M28.56M
Gross Margin47.7%51.9%45.2%41.4%50.1%
Research & Development7.2M9.37M11.55M9.54M6.83M
Selling, General & Admin12.03M15.5M17.24M18.13M16.88M
Operating Expenses19.23M24.87M28.79M27.68M23.71M
Depreciation & Amortization1.18M1.63M2.25M1.87M1.64M
EBITDA1.55M2.21M(3.02M)(5.44M)6.27M
EBITDA Margin3.8%4.5%-5.6%-10.8%11.0%
Operating Income366K607K(4.45M)(6.92M)4.85M
Operating Margin0.9%1.2%-8.3%-13.8%8.5%
Interest Income00000
Interest Expense00000
Other Income / Expenses71K(24K)(818K)(387K)(220K)
Income Before Tax437K583K(5.27M)(7.31M)4.63M
Pre-Tax Margin1.1%1.2%-9.8%-14.6%8.1%
Income Tax Expense75K35K68K(32K)(75K)
Net Income362K548K(5.34M)(7.28M)4.7M
Net Margin0.9%1.1%-9.9%-14.5%8.3%
EPS (Basic)0.030.04(0.39)(0.54)0.34
EPS (Diluted)0.020.04(0.39)(0.54)0.33
Weighted Avg Shares13.14M13.2M13.54M13.55M13.66M
Weighted Avg Shares (Diluted)14.57M14.16M13.54M13.55M14.27M

Champions Oncology, Inc.

NASDAQ:CSBR

Intrinsic Alpha fair value

Locked

Current Price

$4.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.